SCHEMBL24254497

SCHEMBL24254497

CCc1ccc(S(=O)(=O)N(C)C)cc1NC(=O)Cc1ccc(Cl)c(Cl)c1

nearest known ligand 0.56

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.56
LMNA P02545 3/20 0.56
HTT P42858 3/20 0.56
SMN1; SMN2 Q16637 2/20 0.56
MAPT P10636 1/20 0.56
KCNJ6 P48051 2/20 0.51
KCNJ5 P48544 2/20 0.51
KCNJ3 P48549 2/20 0.51
GAA P10253 2/20 0.48
MAPK1 P28482 1/20 0.48
KDM4E B2RXH2 1/20 0.48
GFER P55789 1/20 0.48
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
RORC P51449 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
NPC1 O15118 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24254485 0.91 ALDH1A1 (0.60) ALDH1A1LMNAHTTSMN1; SMN2MAPT
SCHEMBL24254502 0.88 ALDH1A1 (0.66) ALDH1A1LMNAHTTSMN1; SMN2MAPT
SCHEMBL24254529 0.81 ALDH1A1 (0.53) ALDH1A1LMNAHTTSMN1; SMN2MAPT
SCHEMBL24254564 0.81 ALDH1A1 (0.51) ALDH1A1LMNAHTTSMN1; SMN2MAPT
SCHEMBL24254505 0.80 LMNA (0.79) ALDH1A1LMNAHTTSMN1; SMN2MAPT
SCHEMBL24254515 0.79 MAPT (0.48) ALDH1A1LMNAHTTSMN1; SMN2MAPT
SCHEMBL24254513 0.77 ALDH1A1 (0.56) ALDH1A1LMNASMN1; SMN2MAPTGAA
SCHEMBL26188053 0.76 VCAM1 (0.57) ALDH1A1LMNAHTTSMN1; SMN2MAPT
SCHEMBL26188145 0.75 ALDH1A1 (0.64) ALDH1A1LMNAMAPTGAAKMT2A
SCHEMBL26188045 0.74 ALDH1A1 (0.57) ALDH1A1LMNAHTTSMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230271918-A1 SUBSTITUTED 3-AMINO-4-METHYLBENZENESULFONAMIDES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. 2023-08-31 US disclosed
US-20230271918-A1 SUBSTITUTED 3-AMINO-4-METHYLBENZENESULFONAMIDES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. 2023-08-31 US disclosed
WO-2022035804-A1 SUBSTITUTED 3-AMINO-4-METHYLBENZENESULFONAMIDES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. (US) 2022-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230271918-A1 SUBSTITUTED 3-AMINO-4-METHYLBENZENESULFONAMIDES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 USP28, USP30, USP1 ALDH1A1 1387/4885LMNA 3727/4885HTT 2407/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.